Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1986-8-11
pubmed:abstractText
Depression of the cellular immune responses in mice with disseminated histoplasmosis is associated with deficient production of interleukin-2 (IL-2) by splenocytes. Therefore, we examined whether a highly purified preparation of IL-2, recombinant human IL-2 (rIL-2), could modify the cellular immune responses in infected mice and whether this lymphokine could alter the severity of histoplasmosis in animals. Exogenous rIL-2, at concentrations of up to 1,000 U/ml, failed to augment the proliferative responses to concanavalin A by unfractionated splenocytes or splenic T cells from mice infected for 1 week. In addition, rIL-2 did not modulate the plaque-forming cell response to sheep erythrocytes by splenocytes from these same mice. However, at week 3, rIL-2 in concentrations ranging from 10 to 1,000 U/ml considerably augmented the proliferative response to concanavalin A and plaque-forming cell response to sheep erythrocytes by splenocytes from infected mice. Kinetics studies demonstrated that rIL-2 exerted maximal immunoregulatory activity when added on day 0 or 1 to cultures of splenocytes. In vivo administration of rIL-2, 200 to 20,000 U/day, for 10 days to normal and 3-week-infected mice did not alter the proliferative activity of splenocytes to concanavalin A; 200,000 U of rIL-2 per day actually depressed the proliferative responses of splenocytes from normal and infected mice. In vivo, rIL-2 did not modify delayed-type hypersensitivity responses to sheep erythrocytes or to histoplasmin by normal and infected mice. Moreover, treatment with rIL-2 in vivo did not reduce the number of Histoplasma CFU in spleens of mice. Thus, despite the immunoenhancing effect of rIL-2 in vitro, this lymphokine failed to exert similar effects in vivo.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-2989366, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-2993418, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-313371, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3872906, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3877764, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3900209, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3921456, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3925347, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-3932205, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-4503682, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-4544248, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-4587740, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-5653817, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6034749, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6224858, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6230394, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6230399, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6367046, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6407015, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6409427, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6411624, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6453657, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6790656, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6975351, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-6979554, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-7000673, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-7042543, http://linkedlifedata.com/resource/pubmed/commentcorrection/3487507-87425
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0019-9567
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6-12
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Modulation of cellular immune responses in mice with disseminated histoplasmosis by recombinant interleukin-2.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't